Lumosa Therapeutics Co (ROCO:6535) Research & Development: NT$304.37 Mil (TTM As of Dec. 2025)


ROCO:6535 Lumosa Therapeutics Co Ltd ROCO:6535
70 GF Score
Price NT$97.00
GF Value NT$130.67
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lumosa Therapeutics Co Research & Development?

Lumosa Therapeutics Co ROCO:6535 -2.81% 70 Research & Development is NT$304.37 Mil as of Dec. 2025. GuruFocus rates ROCO:6535 with a GF Score™ of 70/100 and a GF Value™ of NT$130.67 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Lumosa Therapeutics Co's Research & Development for the three months ended in Dec. 2025 was NT$45.95 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$304.37 Mil.

Lumosa Therapeutics Co  (ROCO:6535) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Lumosa Therapeutics Co Research & Development Related Terms

Lumosa Therapeutics Co Research & Development Historical Data

* Premium members only.

The historical data trend for Lumosa Therapeutics Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumosa Therapeutics Co Research & Development Chart

Lumosa Therapeutics Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 406.05 280.46 369.30 322.86 304.37

Lumosa Therapeutics Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 110.69 99.75 90.28 68.40 45.95
ROCO:6535
70GF Score
Lumosa Therapeutics Co Ltd ROCO:6535
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lumosa Therapeutics Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$304.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$304.37 Mil mean?
Lumosa Therapeutics Co (ROCO:6535) has a Research & Development of NT$304.37 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Lumosa Therapeutics Co and its competitors.
Is Lumosa Therapeutics Co's Research & Development too high?
Lumosa Therapeutics Co's current Research & Development is NT$304.37 Mil. Overall, Lumosa Therapeutics Co has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lumosa Therapeutics Co's Research & Development compare to VRTX and REGN?
Lumosa Therapeutics Co's Research & Development of NT$304.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Lumosa Therapeutics Co and its competitors. Lumosa Therapeutics Co's current Research & Development is NT$304.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumosa Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, Lumosa Therapeutics Co (ROCO:6535) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$130.67, compared to a current price of NT$97.00 — trading 25.8% below its estimated fair value. The current Research & Development is NT$304.37 Mil. Lumosa Therapeutics Co's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Lumosa Therapeutics Co (ROCO:6535), the current Research & Development is NT$304.37 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?

Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued. The current stock price of NT$97.00 is trading 25.8% below its estimated GF Value™ of NT$130.67. GuruFocus considers Lumosa Therapeutics Co to be Modestly Undervalued.

Key valuation signals for ROCO:6535:

  • Research & Development: NT$304.37 Mil
  • GF Value™: NT$130.67 vs. price of NT$97.00 (25.8% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lumosa Therapeutics Co Business Description

Address Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
70GF Score

Get the complete analysis for ROCO:6535

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$97.00
Price
NT$130.67
GF Value